Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
98 hedge funds and large institutions have $51.6M invested in Insys Therapeutics, Inc. in 2019 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 27 increasing their positions, 18 reducing their positions, and 29 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 18
21% more capital invested
Capital invested by funds: $42.5M → $51.6M (+$9.09M)
13% less funds holding
Funds holding: 113 → 98 (-15)
42% less call options, than puts
Call options by funds: $724K | Put options by funds: $1.24M
45% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.1M |
| 2 |
Renaissance Technologies
New York
|
+$2.72M |
| 3 |
Millennium Management
New York
|
+$1.26M |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$688K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$480K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$5.08M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$2.19M |
| 3 |
D.E. Shaw & Co
New York
|
-$888K |
| 4 |
BlackRock
New York
|
-$544K |
| 5 |
JP Morgan Chase
New York
|
-$366K |
INSY Hedge Fund Activity: Q1 2019 in Review
98 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q1 2019, worth a combined $51.6M — up 21% from $42.5M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of INSY and 16 opened new positions — a net loss of 13 holders — while 18 trimmed existing stakes and 27 added.
The largest buyer was Vanguard Group, adding an estimated $3.1M. The largest seller was ETF Managers Group, exiting entirely with an estimated $5.08M sold.
- 98 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q1 2019, down from 113 in Q4 2018.
- Funds reported $51.6M of Insys Therapeutics, Inc. stock for Q1 2019, up 21% quarter-over-quarter.
- 16 funds opened new Insys Therapeutics, Inc. positions in Q1 2019 and 29 closed out, a net change of -13 holders.
- The largest Insys Therapeutics, Inc. buyer in Q1 2019 was Vanguard Group, an estimated $3.1M added.
- The largest Insys Therapeutics, Inc. seller in Q1 2019 was ETF Managers Group, an estimated $5.08M sold.
Based on aggregated 13F filings for Q1 2019.